BIIB
BiogenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull read is that Q1 showed better-than-feared core execution: revenue and EPS grew year over year, growth products remained strong, LEQEMBI sales kept scaling, and management framed Apellis plus felzartamab as portfolio actions that can improve the medium-term growth mix. The dated May 24 LEQEMBI IQLIK decision adds a near-term regulatory hook.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
2026 non-GAAP EPS guidance was cut to $14.25-$15.25 from $15.25-$16.25, excluding Apellis, due to acquired IPR&D charges tied to business-development activity, with about $0.80 of the impact expected in Q2. [#8-K-2026-04-29]
Momentum
33
Value
68
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $203.00 · Bull $220.00 · Bear $170.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $228.43
Why
Momentum33 · Δ7d -5.3
Value68 · Δ7d +0.1
Sentiment44 · Δ7d -6.8
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
33
26% active weight
Current posture
7d trendFlat
Δ7d
-5.3
Δ21d
-36.4
Value
68
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
44
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.8
Δ21d
+2.6
Why this grade
Composite grade C. Momentum 33.0 / Value 68.5 / Sentiment 43.9
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$29.52B
Beta
0.16
Shares Out
147.64M
P/E (TTM)
15.9
P/S (TTM)
2.55
P/FCF (TTM)
11.33
Rev YoY
+2.9%
EPS YoY
+31.2%
Gross Margin
+66.3%
Op Margin
+21.9%
Net Debt
$2.84B
Current Ratio
3.06
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology